Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2012 / Cilt: 38 - Sayı: 3

Mesane kanseri nedeniyle radikal sistektomi yapılan hastalarda cinsiyetin onkolojik sonuçlara etkisi

The effect of gender on oncological outcomes in patients who have undergone radical cystectomy due to bladder cancer

Pages
126–138
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In terms of overall complications, no significant differences were found between males and females.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate the effect of gender on oncologic results in patients who have undergone radical cystectomy due to bladder cancer.
📊
Key Findings & Data:Materials and methods: We retrospectively reviewed data from 460 patients who had radical cystectomy due to bladder cancer in our clinic.
💡
Conclusion & Impact:In terms of overall complications, no significant differences were found between males and females.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to evaluate the effect of gender on oncologic results in patients who have undergone radical cystectomy due to bladder cancer. Materials and methods: We retrospectively reviewed data from 460 patients who had radical cystectomy due to bladder cancer in our clinic. A total of 420 of the patients were men, and 40 patients were women. We evaluated the tumor type, tumor stage, tumor grade, lymph node involvement status, complications and survival rates of the females. These parameters were compared to male cystectomy data. Results: The median age of male and female patients was 60.59±8.966 and 63.2±7.816, respectively (p=0.076). In total, 79.4% of the males and 70.3% of females had transitional cell cancer (p=0.192). The detection frequencies for pT1, pT2, pT3 vs. pT4 stage tumors in males and females was 18%, 34.2%, 33.4% vs. 14% and 2.8%, 33.3%, 41.7%, 22.2%, respectively. The percentage of the lymph node involvement in female and male patients was 48.5% and 23.9% (p=0.02). The grade 3 tumor involvement in female and male patients was 80.6% and 72.7% (p=0.621). In females, the bladder-confined tumor percentage was 22.2% and males rate was 48.3% (p=0.04). In terms of overall complications, no significant differences were found between males and females. Disease-specific survival (DSS) was 115±42.2 months in males and 18±2.14 months in females. Three-year DSS was 61.4% in males and 15.3% in females (p=0.013). Median overall survival was 47±11.789 months in males and 18±1.581 months in females. Three-year overall survival was 53.2% for males and 11.4% for females. A significant difference was found between males and females (p=0.013). Conclusion: In this study, we found that females present worse disease specific and overall survival rates than males due to poor prognostic factors such as lymph node involvement and the higher prevalence of extravesical disease in female patients.

Özet

Amaç: Bu çalışmanın amacı mesane tümörü nedeniyle radikal sistektomi yapılan hastalarda cinsiyetin onkolojik sonuçlara etkisini değerlendirmektir. Gereç ve yöntem: Kliniğimizde mesane tümörü nedeniyle radikal sistektomi uygulanan 460 hastanın verileri retrospektif olarak incelendi. 420 erkek ve 40 kadın hasta çalışmaya dahil edildi. Kadın sistektomi olgularının tümör tipi, tümör evreleri, tümör derecesi, lenf nodu tutulum oranları, komplikasyonlar ve sağ kalım verileri değerlendirildi. Bu parametreler açısından erkek sistektomi olgularıyla karşılaştırıldı. Bulgular: Erkek hastaların yaş ortalaması 60.59±8.966, kadın hastaların yaş ortalaması ise 63.2±7.816 idi (p=0.076). Erkek hastaların %79.4’ü transizyonel hücreli kanser iken kadın hastalarda bu oran %70.3 idi (p=0.192). Kadın hastalarda pT1, pT2, pT3 ve pT4 evrelerinde tümör saptanma sıklığı sırasıyla %2.8, %33.3, %41.7, %22.2 iken erkeklerde bu oranlar sırasıyla %18, %34.2, %33.4 ve %14 idi. Lenf nodu tutulumu açısından olgular değerlendirildiğinde kadın hastalarda lenf notu tutulma oranı %48.5 iken erkek hastalarda bu oran %23.9 idi (p=0.002). Kadınlarda Grade 3 tümör saptanma oranı %80.6 iken erkeklerde ise %72.7 idi (p=0.335). Kadınlarda mesane sınırlı hastalık bulunma oranı %22.2 iken erkeklerde bu oran %48.3 idi (p=0.04). Kadın ve erkek hastalarda tüm komplikasyonlar değerlendirildiğinde her iki grup arasında istatistiksel anlamlı fark izlenmemiştir (p=0.319). Erkeklerde median hastalığa özgü sağkalım (HÖS) 115±42.2 ay, kadınlarda ise 18 (±2.14) aydı. 3 yıllık hastalığa özgü sağkalım verileri değerlendirildiğinde erkeklerde %61.4, kadınlarda %15.3 olup aralarında istatistiksel anlamlı fark izlenmiştir (p=0.013). Erkeklerde median genel sağkalım (GS) 47 ay (±11.789), kadınlarda ise 18 ay (±1.581) idi. Üç yıllık GS verileri değerlendirildiğinde erkeklerde %53.2, kadınlarda ise %11.4 bulundu. Her iki grup arasında istatistiksel anlamlı fark izlenmiştir (p=0.013). Sonuç: Çalışmamızda sistektomi yapılan kadın hastalarda hastalığa özgü sağkalım, genel sağkalım erkeklere oranla daha kötü bulunmuştur. Bu durumun nedeni çalışmamızda lenf nodu tutulumunun ve mesane dışı hastalık gibi kötü prognostik faktörlerin kadın hastalarda daha fazla olması olarak görülmektedir.

🔖

Cite This Article

ŞEFİK, E., GÖRGEL, S. N., BALCI, U., GİRGİN, M. C., DİNÇEL, Ç. (2012). Mesane kanseri nedeniyle radikal sistektomi yapılan hastalarda cinsiyetin onkolojik sonuçlara etkisi. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 38 - Sayı: 3, 126–138. https://ajindex.com/articles/328057

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30
  2. Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006;175:2048-53
  3. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93
  4. Manunta A, Vincendeau S, Kiriakou G, Lobel B, Guille F. Nontransitional cell bladder carcinomas. BJU Int 2005;95:497-502
  5. Ahmed HU, Arya M, Patel HR. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets. Expert Rev Anticancer Ther 2005;5:1011-22. 6. van der Poel HG, Mungan NA, Witjes JA. Bladder cancer in women. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:207-12
  6. Silverman D, Morrison A, Devesa S, Bladder cancer. In: Scottenfeld D, Fraumeni J, editors. Cancer epidomiology and prevention, second ed. New york: Oxford university pres inc., 1996. p. 1156-79
  7. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990;82:1636-40
  8. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41
  9. Ruiz Cerdá JL, Alfonso Gil R, Domenech Ferrando E, Pascual Bueno J, Vera Donoso CD, Martínez Jabaloyas J, et al. The evolution over time (1960-1990) of mortality and the ratio of males in bladder cancer in Spain. Actas Urol Esp 1995;19:196-202
  10. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34
  11. Murphy WM. Farrow GM. Beckwith B Renal and Bladder Tumors. AFIP Fascicle Series. Washington DC: American Registry of Pathology, 1994 13. Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 1988;48:3853-5
  12. El Sabai I. Cancer of the bladder in Egypt. Proc hit Symp Bilharziasis (Cairo) 1996;1:709-23. 15. van der Poel HG, Mungan NA, Witjes JA. Bladder cancer in women. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:207-12
  13. Dinçel Ç. Üroonkoloji, 1.Baskı. İzmir, Meta Basım Matbaacılık, 2007, s 399-400
  14. Prout G, Mar